An interventional study of ABT13107 and Hyalobarrier in Postoperative Adhesion of Uterus, sponsored by Medy-Tox. Completed at 1 site in Korea, Republic of. Open to female participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-08-25.
Sponsored by Medy-Tox · Not applicable, Interventional, and Treatment
This study is intended to evaluate the efficacy and safety of ABT13107 compared to Hyalobarrier applied to postoperative intrauterine.
241 studies on the registry are indexed under Tissue Adhesions; 29 are open to participants now.
This study's enrollment of 192 is above the median of 60 across 184 interventional studies indexed under Tissue Adhesions.
Browse Tissue Adhesions studies →Medy-Tox is the lead sponsor of 48 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: ABT13107
Device: Hyalobarrier
Dose: 3mL, maximum 10mL
Dose: 10mL
Incidence of intrauterine adhesion
Incidence rate of intrauterine adhesion after surgery
Time frame: 4 weeks
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medy-Tox